Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HS-20094 injection in adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
CTR20253481Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of olatorepatide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Sep 2025; status: active.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20253481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253481.